HK Stock Market Move | INNOGEN-B(02591) rose more than 3% during trading hours. Sulpagleride recommended in the National Basic Diabetes Prevention and Treatment Guidelines.

INNOGEN-B (02591) rose more than 3% in midday trading, up 3.43% to HK$32 as of press time, with a trading volume of HK$2074.21 million. On the news front, according to a message from Yinnuo Pharmaceuticals, under the strategic deployment of promoting the prevention and treatment of diabetes in the "Healthy China 2030 Plan" and improving the accessibility of innovative drugs, China's first original super long-acting human GLP-1 receptor agonist (GLP-1RA) Ersuplegrutide (trade name: Einuoqing ) has officially been included in the national medical insurance drug list for 2025, applicable for "blood sugar control in adult type 2 diabetes patients", and will officially take effect from January 1, 2026. This move marks a key step in the universalization of innovative diabetes treatment in China. In the "National Primary Care Diabetes Prevention and Treatment Management Guidelines (2025)", Ersuplegrutide is listed as a weekly regimen of injectable GLP-1RA for lowering blood sugar, providing direct policy and regulatory basis for the provision and use of this drug in primary care medical institutions. The guidelines emphasize that GLP-1RA is an important treatment choice for adult type 2 diabetes (T2DM) patients with atherosclerotic cardiovascular disease (ASCVD) or its risk factors, heart failure, chronic kidney disease (CKD), as well as overweight and obese patients in need of weight management.